Research Use Only: This article is for qualified laboratory staff carrying out in-vitro assays or approved model-animal research. It is not a guide for human or veterinary use.
The preparation and testing information below must not be turned into injection instructions, personal-use concentrations, or dosing schedules.
Cagrilintide, also known in research papers as AM833 or NN0174-0833, is a modified 37-amino-acid amylin analogue. Intact cagrilintide—including the Lys1-linked γ-Glu–C20 fatty-diacid moiety, the Cys2–Cys7 intramolecular disulfide bond, and C-terminal amidation, and excluding variable counterions and solvate water—has the molecular formula C194H312N54O59S2 and an average molecular mass of approximately 4409.1 Da (monoisotopic mass 4406.25 Da, exact mass 4408.26 Da).

Computed properties from PubChem (CID 171397054) include an XLogP3-AA of −12.5, a topological polar surface area of 1880 Ų, 60 hydrogen bond donors, and 65 hydrogen bond acceptors. The peptide backbone alone—excluding the γ-Glu–C20 diacid appendage—has an approximate mass of 3955.5 Da, illustrating that approximately 454 Da of the total mass comes from the N-terminal lipid modification.[1][2][3]
Published pharmacology and structural studies support cagrilintide’s classification as a non-selective agonist in the calcitonin receptor family. Active Gs-coupled receptor structures have been reported for CTR and all three amylin receptor types—demonstrating that cagrilintide can form stable receptor complexes under the study conditions—but potency, efficacy, signaling kinetics, and receptor regulation must be measured separately for each receptor construct and assay system.[6][7]
Molecular Identity
| Item | Information | Important note |
|---|---|---|
| Research names | Cagrilintide; AM833; NN0174-0833 | The name on the vial should match the lot-specific COA and identity test. |
| CAS number | 1415456-99-3 | The salt form, acetate content, and water content should be listed separately when relevant. |
| Peptide length | 37 amino acids | The peptide is C-terminally amidated and contains an intramolecular Cys2–Cys7 disulfide bond. |
| Sequence representation | (C20 fatty diacid–γ-Glu)-KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2 (intramolecular disulfide: Cys2–Cys7) |
The Lys1-linked γ-Glu–C20 diacid group contributes approximately 454 Da to the total molecular mass. The sequence notation excluding this modification is the peptide backbone alone. |
| Main changes from the pramlintide-like backbone | N14E, V17R, and Y37P | Residue 37 is Pro, not Tyr. It is not the lipid attachment site. |
| Lipid attachment | C20 fatty diacid attached to Lys1 through a γ-Glu linker | The lipid is attached near the N-terminus, not at the C-terminus. |
| Molecular formula of intact cagrilintide | C194H312N54O59S2 | This formula describes intact cagrilintide including the Lys1-linked γ-Glu–C20 diacid moiety and the Cys2–Cys7 disulfide bond; it does not include variable acetate or water content. |
| Average molecular mass of intact cagrilintide | 4409.1 Da (monoisotopic: 4406.25 Da; exact: 4408.26 Da) | Use peptide content, water, and counterion data from the COA for accurate weighing calculations. The peptide backbone alone (excluding the γ-Glu–C20 diacid) has an approximate mass of 3955.5 Da. |
The development paper describes cagrilintide as a stabilized and lipidated amylin analogue built from a pramlintide-like sequence. The N14E and V17R changes help stabilize the peptide helix through a Glu14–Arg17 salt bridge interaction, while the Y37P change and Lys1 lipidation alter receptor interaction and exposure properties.
The C20 fatty diacid allows reversible albumin binding and prolongs systemic exposure, supporting once-weekly administration in the studied regulated product context. In mini-pig pharmacokinetic studies, the terminal half-life was approximately 170 hours following subcutaneous administration.[3]
A 2025 cryo-EM study produced active-state, Gs-coupled structures of cagrilintide bound to CTR, AMY1R, AMY2R, and AMY3R. The receptor-bound structures were consistent with the known Cys2–Cys7 disulfide bond, C-terminal amidation, and Lys1 lipidation.
Density for the γ-Glu linker and only a short portion of the fatty-acid chain was resolved in selected maps; the remainder of the C20 lipid tail was not visualized.[7]
Salt-form note: A cagrilintide acetate lot can contain acetate and water in addition to the peptide. For this reason, the intact cagrilintide molecular mass alone should not be used as the total mass of the supplied solid.
PubChem records a GHS reproductive toxicity classification (Category 2) for cagrilintide, noting that it is suspected of damaging the unborn child—a classification relevant to laboratory risk assessment and handling procedures.[1][2]
How the Receptors Are Built
The calcitonin receptor, or CTR, is a class B1 G-protein-coupled receptor. When CTR combines with receptor activity-modifying protein 1, 2, or 3, it forms the AMY1R, AMY2R, or AMY3R receptor type.[4][5]
| Receptor type | Composition | What this means in an experiment |
|---|---|---|
| CTR | CTR expressed without an exogenously introduced RAMP | Used as the reference calcitonin-receptor system. Host cells may express endogenous RAMPs; the CTR isoform and expression levels should be reported. |
| AMY1R | CTR + RAMP1 | RAMP1 changes ligand binding and receptor signaling. |
| AMY2R | CTR + RAMP2 | Its activity should be measured directly and not guessed from other receptor types. |
| AMY3R | CTR + RAMP3 | Commonly included in cagrilintide binding and cAMP tests. The 2025 mouse study suggests roles for AMY1R and AMY3R in body-weight regulation. |
RAMPs can change ligand affinity, receptor movement inside the cell, and the strength of the signal. A useful experiment should therefore report the CTR form, the RAMP used, the host cell, and how receptor expression was checked.[5]
What Cagrilintide Does in Cell Assays
The main comparative pharmacology study examined AM833 across 25 binding, activation, and receptor-regulation measurements in CTR and amylin-receptor systems. It described AM833 as a non-selective agonist in this receptor family.
This does not mean that every receptor responds at the same concentration, reaches the same maximum response, or stays active for the same length of time.[6]
Canonical cAMP pathway
A canonical and commonly measured signaling mechanism for CTR and amylin receptors is coupling to Gs, activation of adenylyl cyclase, and an increase in intracellular cAMP. In the comparative pharmacology study, additional G-protein pathways (including Gi1, G11, and G12) were also evaluated, so the cAMP pathway represents one well-characterized component of a broader signaling profile rather than the exclusive mechanism.
The cAMP signal can then affect PKA and other cAMP-sensitive proteins depending on the cell type.[5][6]
- Cagrilintide binds to CTR or a CTR/RAMP receptor complex.
- The activated receptor couples to intracellular G proteins.
- Gs activates adenylyl cyclase in the test cell.
- Adenylyl cyclase raises intracellular cAMP.
- The cAMP signal can then affect PKA and other cAMP-sensitive proteins.
The exact downstream result depends on the cell type. A cAMP increase alone does not prove changes in potassium channels, calcium channels, hormone release, or a whole-animal response.[5][6]
Binding time and receptor regulation
In the published kinetic binding tests, AM833 showed relatively short receptor residence times—approximately 3.22 minutes at CTR, 5.40 minutes at AMY1R, and 3.64 minutes at AMY3R in the studied systems. Salmon calcitonin stayed bound for much longer in the same study.
These residence-time values are specific to the kinetic binding assay used and should not be interpreted as plasma half-life, pharmacodynamic duration, or in vivo exposure time.[6]
Residence time should be measured with a kinetic binding method. The time needed for cAMP to return to baseline is a different measurement. β-arrestin recruitment, receptor internalization, recycling, and desensitization are also separate tests, so one result should not be used as proof of all the others.
What the Structural Study Showed
The 2025 cryo-EM study reported active, Gs-coupled structures of cagrilintide bound to CTR, AMY1R, AMY2R, and AMY3R. The structures demonstrate that cagrilintide can form stable, active-state complexes with all four receptor types under the study conditions—they do not establish that the four receptor subtypes have equal affinity, potency, or physiological importance in every tissue.[7]
- Similar overall binding: Cagrilintide used an amylin-like binding mode at the four receptor types, with the peptide adopting a continuous α-helical conformation spanning the receptor transmembrane domain.
- Mid-peptide shape: Residues around Ser19–Pro25 formed the characteristic amylin “bypass” shape that allows the peptide to fit within the receptor binding pocket.
- Glu14–Arg17 interaction: An electrostatic salt bridge between Glu14 and Arg17 helped stabilize the peptide helix, consistent with the engineering rationale described in the discovery paper.
- Lys1 lipidation: Density for the γ-Glu linker and a short portion of the fatty-acid chain was resolved in selected maps; the remainder of the C20 lipid tail was not visualized.
- Pro37: The C-terminal Pro37 altered contacts near the extracellular domain compared with the Tyr found at the corresponding position in native amylin.
The structural and functional evidence should be read at different levels: the structures show that receptor complexes form under cryo-EM conditions, while the functional studies provide quantitative measurements of binding, activation, and receptor regulation. One level of evidence does not substitute for the other.[7]
Findings From Model-Animal Research
A 2025 study used male high-fat-diet mice in which both RAMP1 and RAMP3 had been deleted—a whole-body double knockout that may involve developmental compensation and should not be directly extrapolated to quantify human receptor contributions. During the three-week experiment, the measured body-mass response to cagrilintide was strongly reduced in the double-knockout mice compared with wild-type mice.
After acute exposure, staining for cFos, a marker often used to show neuronal activation, was approximately 57% lower in the area postrema of the double-knockout group compared with wild-type controls.[8]
The same study found cFos responses in brain regions including the dorsal vagal complex and lateral parabrachial nucleus. These are findings from a specific mouse model.
They indicate that AMY1R and AMY3R contribute to the body-weight-lowering effects of cagrilintide in this experimental system, but they do not show that AMY2R or CTR is inactive in every tissue or irrelevant to every pharmacological endpoint. These results should not be treated as a substitute for direct receptor-binding or functional tests in the relevant experimental model.[8]
Laboratory Solution Preparation and Handling
Laboratory Use Only: This section concerns analytical and in-vitro assay solutions prepared by trained laboratory staff. It is not a human or veterinary administration protocol.
There is no single reconstitution concentration, solvent, pH, storage temperature, or solution shelf life that can be applied to every cagrilintide lot and every assay. Use the lot-specific COA or product documentation together with a laboratory-validated method.
Before preparing a stock solution
- Confirm the material name, salt form, peptide content, purity, water, and counterion data.
- Calculate concentration from peptide content when that value is available, rather than assuming the full vial mass is pure peptide. The intact cagrilintide molecular mass (4409.1 Da) should be used for the peptide-equivalent mass; do not use the peptide-backbone-only mass (~3955.5 Da) unless the COA explicitly reports content on that basis.
- Check solubility and recovery in the actual assay buffer at the required concentration.
- Record the serum or albumin level because the C20 lipid can change the free peptide concentration.
- Use a validated low-binding container if adsorption is a concern.
- Prepare small aliquots when appropriate and avoid unnecessary freeze-thaw cycles.
- Do not claim a solution shelf life without stability data for the same solvent, container, temperature, and concentration.
Lipidated peptides can adsorb to containers or behave differently in buffers containing serum proteins. For that reason, assay concentration should be supported by a tested preparation method rather than by dilution mathematics alone.[3][6]
How to Read the COA
A COA is a record of test results for one production lot. It should not be reduced to a single HPLC purity value.
General principles from ICH Q2(R2) may help with analytical-method validation, and ICH Q3C provides a framework for residual-solvent classification and limits. ICH Q6A discusses specification-setting for new drug substances of synthetic chemical origin and may be selectively applicable to certain low-molecular-weight synthetic peptides, but ICH Q6B does not directly apply to synthetic peptides such as cagrilintide.[9][10]
| COA item | What it tells you | What it does not prove by itself |
|---|---|---|
| RP-HPLC or UHPLC | The relative chromatographic purity and impurity pattern under the stated method. For a lipidated 37-residue peptide, area purity should be supplemented by related-substance profiling including aggregation, oxidation, and deamidation products. | Full molecular identity, peptide content by weight, sterility, or biological suitability |
| Mass spectrometry | Whether the observed molecular mass agrees with the expected intact cagrilintide identity. ESI-MS of a ~4.4 kDa lipidated peptide typically produces multiple charge states requiring deconvolution. | Chromatographic purity or accurate peptide quantity without a separate quantitative method; does not independently confirm the exact lipidation site or disulfide connectivity |
| Sequence / peptide mapping | Whether the amino-acid sequence, terminal modifications, and site-specific lipidation (Lys1) match the intended structure, when supported by LC-MS/MS fragmentation or another justified method. | Purity unless tested separately; intact-mass MS alone does not confirm sequence order or modification sites |
| Peptide content or assay | The amount of peptide in the weighed material, stated with the calculation basis (e.g., as-is, anhydrous, counterion-free, or peptide-equivalent). | Identity unless supported by another test |
| Water | The moisture contribution to the supplied mass | Residual solvent levels |
| Counterion content | The amount of acetate or another counterion | Peptide purity |
| Residual solvents | Measured residues from solvents used during manufacture | Peptide-related impurity levels |
| Endotoxin, bioburden, sterility, and particulate control | Results for the named tests when included in the specification. These attributes should be defined according to the intended in vivo use, route of administration, and institutional protocol. | Cannot be inferred from HPLC purity or mass spectrometry alone; endotoxin testing is not equivalent to sterility testing |
Electrospray mass spectrometry can give several differently charged ions for a peptide of approximately 4.4 kDa. The COA should therefore explain whether the reported result is one ion, a group of charge states, or a calculated intact mass.
A single unexplained m/z value is not sufficient for a clear identity check. Average molecular weight, monoisotopic mass, deconvoluted mass, and observed m/z values at specific charge states are distinct parameters and should not be used interchangeably.[11]
FDA guidance states that analytical methods used to support identity, strength, quality, purity, and potency should be suitable for their intended purpose and supported by appropriate validation information.[10]
COA limitation: COA, HPLC, and mass-spectrometry results are laboratory quality-control records. They do not prove safety, clinical effectiveness, sterility, or suitability for human or veterinary administration.
Summary
Active Gs-coupled complexes have been structurally resolved for CTR, AMY1R, AMY2R, and AMY3R under cryo-EM study conditions. Functional studies support agonist activity within the calcitonin-receptor family, although potency, efficacy, signaling kinetics, and receptor regulation must be measured separately for each receptor construct and assay system.
In the tested mouse model, AMY1R and AMY3R contributed to the body-weight-lowering effects of cagrilintide. The size and duration of a response depend on the receptor system, cell model, assay design, and experimental conditions.[6][7][8]
Authoritative Sources
- U.S. FDA Global Substance Registration System: Cagrilintide substance record.
- NCBI PubChem: Cagrilintide, CID 171397054. Average MW 4409 g/mol, monoisotopic 4406.25 Da, CAS 1415456-99-3, UNII AO43BIF1U8.
- Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021;64(15):11183-11194. N14E, V17R, Y37P; Glu14-Arg17 salt bridge; Lys1-C20 diacid-γGlu; terminal half-life ~170 h mini-pig s.c.
- Christopoulos G, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology. 1999;56(1):235-242.
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family receptors: IUPHAR Review 25. British Journal of Pharmacology. 2018;175(1):3-17.
- Fletcher MM, Keov P, Truong TT, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors. Journal of Pharmacology and Experimental Therapeutics. 2021;377(3):417-440. 25 binding/activation/regulation measurements; CTR ~3.22 min, AMY1R ~5.40 min, AMY3R ~3.64 min receptor residence times.
- Cao J, Belousoff MJ, Johnson RM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. 2025;16:3389. Cryo-EM structures of CTR/AMY1R/AMY2R/AMY3R Gs complexes; γGlu linker resolved, most of C20 tail not visualized.
- Carvas AO, Leuthardt AS, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025;118:105836. RAMP1/RAMP3 double-KO mice; 3-week study; area postrema cFos ~57% lower.
- International Council for Harmonisation: Quality Guidelines. ICH Q2(R2) for analytical-method validation; ICH Q3C for residual solvents; ICH Q6A selectively applicable to certain synthetic peptides; ICH Q6B does not directly apply to synthetic peptides.
- U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics.
- Parker CE, Borchers CH. Mass Spectrometry for Proteomics. NCBI Bookshelf. Average MW, monoisotopic mass, deconvoluted mass, and observed m/z at specific charge states are distinct parameters.
Research Use Only Disclaimer
Research Use Only: The cagrilintide material described on this page is intended solely for qualified laboratory research and is not approved for human or veterinary administration. This article provides an informational summary of published preclinical receptor pharmacology, structural biology, and laboratory quality-control principles.
It does not provide a dosing, administration, or treatment protocol and does not constitute medical, clinical, veterinary guidance or treatment advice. Any animal research must be conducted under applicable institutional approvals and legal requirements.
Laboratories are responsible for checking the lot-specific COA, supplier documentation, institutional requirements, and applicable local rules before starting an experiment. No test result or literature citation on this page establishes suitability for human, veterinary, cosmetic, food, or personal use.